Janssen Biotech announced new five-year data from three pivotal Phase 3 studies evaluating Simponi (golimumab) 50mg administered subcutaneously once every four weeks in the treatment of moderately to ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

First Anti-TNF Infusion Therapy Approved in More Than a Decade for Patients Living with Moderately to Severely Active Rheumatoid Arthritis "Phase 3 data showed treatment with SIMPONI ARIA plus ...

New Phase 3 study findings show that subcutaneous induction regimens of Simponi (golimumab; Janssen Biotech, Inc.) induced clinical response in a majority of patients with moderately to severely ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

HORSHAM, Pa., Sept. 30, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA ® ...

Please provide your email address to receive an email when new articles are posted on . Janssen Biotech announced that the FDA has expanded the labeling provisions for Simponi Aria infusions in ...

LEIDEN, Netherlands, May 27, 2016 /PRNewswire/ -- Janssen Biologics B.V. (Janssen) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...

Sometimes follow-on drugs are flubs that would have been better put in the trash can, but I don't think that'll be the case for Johnson & Johnson's (NYSE:JNJ) Simponi: it was approved on Friday for ...

Remicade (infliximab), a biologic drug for the treatment of rheumatoid arthritis and other autoimmune diseases, remains the top growth driver for Johnson & Johnson (JNJ). Positioning two new ...